Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 3 1Phase 2/3 1Phase 2 1

Status

Completed 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2

Conditions

Lymphoma, T-Cell, Peripheral 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Lymphoma, B-Cell 1

Interventions

Rituximab 169Cyclophosphamide 158fludarabine 76Lenalidomide 73Vincristine 70fludarabine phosphate 63Etoposide 59Doxorubicin 56Prednisone 54venetoclax 49Cytarabine 48Dexamethasone 43Filgrastim 39Peripheral Blood Stem Cell Transplantation 38Methotrexate 38Bendamustine Hydrochloride 38ibrutinib 37obinutuzumab 36Gemcitabine 31pembrolizumab 27Melphalan 27Bortezomib 27Alemtuzumab 25Radiotherapy 23Nivolumab 21Carboplatin 21Tacrolimus 20Granulocyte Colony-Stimulating Factor 20Busulfan 20Whole-Body Irradiation 19

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × prednisolone phosphate × Lymphoid × Clear all
NCT03586999 2024-10-29

Nivolumab With Standard of Care Chemotherapy for Peripheral T Cell Lymphomas

University of Colorado, Denver

Phase 1/2 Completed
18 enrolled 14 charts
Lymphoid

Lymphoma, T-Cell, Peripheral

NCT01897571 2024-03-26

Study of Tazemetostat as Single Agent in Solid Tumors or B-cell Lymphomas and in Combination With Prednisolone in DLBCL

Ipsen

Phase 1/2 Completed
400 enrolled 22 charts 1 FDA
Lymphoid

Lymphoma, Follicular, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡